Advanced Search

Study Preview



Study Title and Description

A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults.



Key Questions Addressed
1 Is this an intervention study?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults.
Author Vulevic J., Juric A., Tzortzis G., Gibson GR.
Country Department of Food and Nutritional Sciences, Food Microbial Sciences, and.
Year 2013
Numbers Pubmed ID: 23303873

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Fiber 4.1
Arms
No arms have been defined in this extraction form.

Design Details
Question... Follow Up Answer Follow-up Answer
pubyear 2013
  • Comments Comments (
    0
    ) |
country United Kingdom
  • Comments Comments (
    0
    ) |
design Randomized Controlled Trial (Crossover)
  • Comments Comments (
    0
    ) |
blindness Double blind
  • Comments Comments (
    0
    ) |
diet Isocaloric/Maintenance
  • Comments Comments (
    0
    ) |
feedcontrol Food partially provided
  • Comments Comments (
    0
    ) |
sampsize 48
  • Comments Comments (
    0
    ) |
runin Unspecified
  • Comments Comments (
    0
    ) |
washout Yes
  • Comments Comments (
    0
    ) |
dosechange No
  • Comments Comments (
    0
    ) |
age_adult 1
  • Comments Comments (
    0
    ) |
age_adol
  • Comments Comments (
    0
    ) |
age_child
  • Comments Comments (
    0
    ) |
age_baby
  • Comments Comments (
    0
    ) |
age_infant
  • Comments Comments (
    0
    ) |
age_oth
  • Comments Comments (
    0
    ) |
age_mean ~44.6
  • Comments Comments (
    0
    ) |
age_range
  • Comments Comments (
    0
    ) |
bmi_mean ~31.4
  • Comments Comments (
    0
    ) |
bmi_range
  • Comments Comments (
    0
    ) |
blhealth_healthy
  • Comments Comments (
    0
    ) |
blhealth_hyperlip
  • Comments Comments (
    0
    ) |
blhealth_diab
  • Comments Comments (
    0
    ) |
blhealth_hyperten
  • Comments Comments (
    0
    ) |
blhealth_digest
  • Comments Comments (
    0
    ) |
blhealth_met
  • Comments Comments (
    0
    ) |
blhealth_oth 1
  • Comments Comments (
    0
    ) |
blhealth_othspec overweight, with 3 or more markers of metabolic syndrome
  • Comments Comments (
    0
    ) |
gender 36
  • Comments Comments (
    0
    ) |
ftype1 Galactooligosaccharide
  • Comments Comments (
    0
    ) |
descrip1_1
  • Comments Comments (
    0
    ) |
descrip1_2
  • Comments Comments (
    0
    ) |
dose1_1 5.5
  • Comments Comments (
    0
    ) |
dose1_2
  • Comments Comments (
    0
    ) |
duration1 12 weeks
  • Comments Comments (
    0
    ) |
admin1 Powder
  • Comments Comments (
    0
    ) |
ftype2
  • Comments Comments (
    0
    ) |
descrip2_1
  • Comments Comments (
    0
    ) |
descrip2_2
  • Comments Comments (
    0
    ) |
dose2_1
  • Comments Comments (
    0
    ) |
dose2_2
  • Comments Comments (
    0
    ) |
duration2
  • Comments Comments (
    0
    ) |
admin2
  • Comments Comments (
    0
    ) |
ftype3
  • Comments Comments (
    0
    ) |
descrip3_1
  • Comments Comments (
    0
    ) |
descrip3_2
  • Comments Comments (
    0
    ) |
dose3_1
  • Comments Comments (
    0
    ) |
dose3_2
  • Comments Comments (
    0
    ) |
duration3
  • Comments Comments (
    0
    ) |
admin3
  • Comments Comments (
    0
    ) |
ftype4
  • Comments Comments (
    0
    ) |
descrip4_1
  • Comments Comments (
    0
    ) |
descrip4_2
  • Comments Comments (
    0
    ) |
dose4_1
  • Comments Comments (
    0
    ) |
dose4_2
  • Comments Comments (
    0
    ) |
duration4
  • Comments Comments (
    0
    ) |
admin4
  • Comments Comments (
    0
    ) |
comparator1 placebo
  • Comments Comments (
    0
    ) |
cdose1 0
  • Comments Comments (
    0
    ) |
cduration1 12 weeks
  • Comments Comments (
    0
    ) |
cadmin1 Powder
  • Comments Comments (
    0
    ) |
comparator2
  • Comments Comments (
    0
    ) |
cdose2
  • Comments Comments (
    0
    ) |
cduration2
  • Comments Comments (
    0
    ) |
cadmin2
  • Comments Comments (
    0
    ) |
comparator3
  • Comments Comments (
    0
    ) |
cdose3
  • Comments Comments (
    0
    ) |
cduration3
  • Comments Comments (
    0
    ) |
cadmin3
  • Comments Comments (
    0
    ) |
comparator4
  • Comments Comments (
    0
    ) |
cdose4
  • Comments Comments (
    0
    ) |
cduration4
  • Comments Comments (
    0
    ) |
cadmin4
  • Comments Comments (
    0
    ) |


Baseline Characteristics
No baseline characteristics have been defined for this extraction form.



Results & Comparisons

No Results found.
Adverse Events
Arm or Total Title Description Comments

Quality Dimensions
No quality dimensions were specified.

Quality Rating
No quality rating data was found.